argenx SE (BSP:A1RG34) Other Net Income (Loss) : R$-0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is argenx SE Other Net Income (Loss)?

argenx SE's Other Net Income (Loss) for the three months ended in Mar. 2025 was R$-0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 was R$-0 Mil.

argenx SE's quarterly Other Net Income (Loss) stayed the same from Sep. 2024 (R$0 Mil) to Dec. 2024 (R$0 Mil) but then declined from Dec. 2024 (R$0 Mil) to Mar. 2025 (R$-0 Mil).

argenx SE's annual Other Net Income (Loss) declined from Dec. 2022 (R$0 Mil) to Dec. 2023 (R$0 Mil) but then stayed the same from Dec. 2023 (R$0 Mil) to Dec. 2024 (R$0 Mil).

argenx SE Other Net Income (Loss) Historical Data

The historical data trend for argenx SE's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Other Net Income (Loss) Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

argenx SE Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

argenx SE Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-0 Mil.

argenx SE Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of argenx SE's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (BSP:A1RG34) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines